SACHS BRUCE I

VRTX Director Sachs purchased 5,000 shares at $389.68 avg on 2025-08-06, now holding 45,000 shares (+12.5%)

Bruce Sachs, a Vertex Pharmaceuticals director, executed 2 separate purchases totaling 5,000 shares for $1,948,415.68 at an average price of $389.68 on August 6, 2025. The transaction increased his holdings by 12.5% to 45,000 shares. The buy occurred when VRTX is trading 27.3% below its 52-week high and down 19.4% over the prior 30 days, placing the stock in a significantly depressed price environment relative to recent history. At the same-ticker level, Sachs' 5 prior trades at VRTX were all sales, with only 1 of 5 showing positive post-trade performance at the 90-day mark; his cross-ticker track record across 9 prior sales shows a 90-day well-timed rate of 11.11%, suggesting limited predictive accuracy in past transactions. The company remains unprofitable on a full-year basis despite strong quarterly performance ($3.0B revenue, $1.0B net income), presenting a mixed fundamental picture against this material open-market accumulation by a board member.

Director Bruce I. Sachs sold 5,295 shares of VRTX at $508.00 on 2024-08-01; post-transaction holdings: 40,000 shares.

Director Sachs sold 5,295 shares (11.7% reduction in holdings) at $508.00 on 2024-08-01, leaving him with 40,000 shares. The transaction occurred near VRTX's 52-week high of $505.78, and the stock has since declined 2.2% from that peak. Examining his prior trades at VRTX specifically, Sachs has executed 5 prior sells; none were well-timed at the 90-day mark (0 of 4 measurable prior sells preceded downturns). His cross-ticker track record across 8 prior sells shows an average 90-day return of +5.2% and a well-timed rate of 0.00%, indicating that sells have consistently been followed by stock appreciation rather than declines. The current fundamental backdrop shows VRTX is unprofitable (net income $-3.6B in the latest quarter) with a P/E of 35.19, though revenue grew 10.5% year-over-year. Without a stated trading plan flag, this appears to be a discretionary transaction at a high-conviction price point, but his historical pattern of poorly-timed sales at this ticker suggests the timing decision merits monitoring.